Indications & Dose:

Multiple myeloma (newly diagnosed) in patients not eligible for transplant, given in combination with dexamethasone until disease progression

BY MOUTH

Adult: 25 mg once daily for 21 consecutive days of repeated 28-day cycles, for doses of dexamethasone, and dose adjustments due to side-effects, consult product literature

Multiple myeloma (newly diagnosed) in patients not eligible for transplant, given in combination with melphalan and prednisone followed by maintenance monotherapy

BY MOUTH

Adult: 10 mg once daily for 21 consecutive days of repeated 28-day cycles for up to 9 cycles, for doses of melphalan and prednisone, and dose adjustments due to side- effects, consult product literature

Multiple myeloma in patients who have received at least one prior therapy, given in combination with dexamethasone

BY MOUTH

Adult: 25 mg once daily for 21 consecutive days of repeated 28-day cycles, for doses of dexamethasone,and dose adjustments due to side-effects, consult product literature

Treatment of transfusion-dependent anaemia due to lowor intermediate-1-risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other treatment options are insufficient or inadequate

BY MOUTH

Adult: 10 mg once daily for 21 consecutive days of repeated 28-day cycles, for dose adjustments due to side-effects, consult product literature

Contraindications:

-

Cautions:

High tumour burden-risk of tumour lysis syndrome . patients with risk factors for myocardial infarction

Precautions:

-

Interaction:

-

Warnings:

-

Adverse Effects:

-

Lactations:

-

Special Precautions:

-

Counselling:

-

Side Effects Or Adverse Reactions:

-

Patient And Carer Advice:

-